KPX Lifescience.Co.Ltd (KQ:114450) — Market Cap & Net Worth
Market Cap & Net Worth: KPX Lifescience.Co.Ltd (114450)
KPX Lifescience.Co.Ltd (KQ:114450) has a market capitalization of $22.26 Million (₩32.85 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #24846 globally and #1793 in its home market, demonstrating a -3.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KPX Lifescience.Co.Ltd's stock price ₩2190.00 by its total outstanding shares 15000000 (15.00 Million). Also see KPX Lifescience.Co.Ltd (114450) total assets for a full breakdown of the balance sheet.
KPX Lifescience.Co.Ltd Market Cap History: 2015 to 2026
KPX Lifescience.Co.Ltd's market capitalization history from 2015 to 2026. Data shows change from $33.22 Million to $22.26 Million (-2.86% CAGR). Also see cash efficiency ratio of KPX Lifescience.Co.Ltd for how efficiently the company converts equity into cash flow.
Index Memberships
KPX Lifescience.Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$233.34 Billion | 0.01% | #941 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$233.34 Billion | 0.01% | #941 of 1384 |
Weight: KPX Lifescience.Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
KPX Lifescience.Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KPX Lifescience.Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check KPX Lifescience.Co.Ltd stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.00x
KPX Lifescience.Co.Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
KPX Lifescience.Co.Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $33.22 Million | $45.51 Billion | $5.39 Billion | 0.00x | 0.01x |
| 2016 | $34.42 Million | $43.30 Billion | $4.50 Billion | 0.00x | 0.01x |
| 2017 | $32.44 Million | $42.58 Billion | $2.22 Billion | 0.00x | 0.01x |
| 2018 | $32.40 Million | $32.75 Billion | -$1.45 Billion | 0.00x | N/A |
| 2019 | $47.04 Million | $37.62 Billion | $1.20 Billion | 0.00x | 0.04x |
| 2020 | $93.39 Million | $24.56 Billion | -$1.06 Billion | 0.00x | N/A |
| 2021 | $77.00 Million | $25.34 Billion | -$3.14 Billion | 0.00x | N/A |
| 2022 | $45.21 Million | $36.50 Billion | -$3.53 Billion | 0.00x | N/A |
| 2023 | $22.62 Million | $22.37 Billion | -$16.36 Billion | 0.00x | N/A |
| 2024 | $16.31 Million | $24.86 Billion | $1.56 Billion | 0.00x | 0.01x |
Competitor Companies of 114450 by Market Capitalization
Companies near KPX Lifescience.Co.Ltd in the global market cap rankings as of September 18, 2026. Review KPX Lifescience.Co.Ltd tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to KPX Lifescience.Co.Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5752 globally with a market cap of $2.26 Billion USD ( ₩3.34 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8322 globally with a market cap of $1.14 Billion USD ( ₩1.69 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9400 globally with a market cap of $895.63 Million USD ( ₩1.32 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10937 globally with a market cap of $654.17 Million USD ( ₩965.30 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5752 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.26 Billion | ₩156100.00 |
| #8322 | ST Pharm Co.Ltd | KQ:237690 | $1.14 Billion | ₩90400.00 |
| #9400 | NatureCell Co.Ltd | KQ:007390 | $895.63 Million | ₩24900.00 |
| #10937 | Oscotec Inc | KQ:039200 | $654.17 Million | ₩34350.00 |
KPX Lifescience.Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, KPX Lifescience.Co.Ltd's market cap moved from $33.22 Million to $ 22.26 Million, with a yearly change of -2.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩22.26 Million | -24.48% |
| 2025 | ₩29.48 Million | +80.80% |
| 2024 | ₩16.31 Million | -27.91% |
| 2023 | ₩22.62 Million | -49.97% |
| 2022 | ₩45.21 Million | -41.29% |
| 2021 | ₩77.00 Million | -17.55% |
| 2020 | ₩93.39 Million | +98.54% |
| 2019 | ₩47.04 Million | +45.18% |
| 2018 | ₩32.40 Million | -0.12% |
| 2017 | ₩32.44 Million | -5.74% |
| 2016 | ₩34.42 Million | +3.59% |
| 2015 | ₩33.22 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of KPX Lifescience.Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.26 Million USD |
| MoneyControl | $22.26 Million USD |
| MarketWatch | $22.26 Million USD |
| marketcap.company | $22.26 Million USD |
| Reuters | $22.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more